Advertisement

Advertisement
Breast Cancer

Imlunestrant, Alone and Combined With Abemaciclib, Effective in ESR1-Mutated Breast Cancer

Imlunestrant, an investigational next-generation oral selective estrogen receptor degrader (SERD), significantly improved progression-free survival vs standard of care in patients with ESR1-mutated breast cancer, according to data from the phase III EMBER-3 trial, presented by Komal Jhaveri, MD, FACP, of Memorial Sloan Kettering Cancer Center, New York, during the 2024 San Antonio Breast Cancer Symposium. In addition, imlunestrant plus abemaciclib significantly improved progression-free survival in all patients regardless of ESR1-mutation status (Abstract GS1-01).


Breast Cancer

BRCA-Mutation Carriers With Prior Diagnosis of Early-Onset Breast Cancer May Benefit From Risk-Reducing Surgery

Patients with germline BRCA gene mutations and a history of early-onset breast cancer who underwent a bilateral risk-reducing mastectomy and/or a risk-reducing salpingo-oophorectomy had lower rates of recurrence, secondary breast and/or ovarian malignancies, and death than those who did not undergo these surgeries, according to the results of a study presented by Matteo Lambertini, MD, PhD, of the University of Genova–IRCCS Ospedale Policlinico San Martino, at the 2024 San Antonio Breast Cancer Symposium (Abstract GS1-08).

Leukemia

Combination of Two Oral Agents May Improve Progression-Free Survival in Patients With Previously Untreated CLL

A combination of the oral drugs acalabrutinib and venetoclax may be more effective at improving progression-free survival and minimizing serious adverse events in patients with previously untreated chronic lymphocytic leukemia (CLL) compared with one of two standard multidrug treatment regimens, according to recet findings presented by Brown et al at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 1009).


Advertisement
Multiple Myeloma

High-Fiber Diet May Slow Disease Progression to Multiple Myeloma

Recent data suggest that a plant-based diet rich in fiber may help to improve the outlook for people with precursor conditions that can lead to multiple myeloma. The research, which involved a 12-week controlled diet with additional health coaching for 20 patients as well as experiments in mice, is reportedly the first interventional study to demonstrate that fiber-focused dietary modifications have the potential to slow the progression of blood cancers. The study was presented by Urvi A. Shah, MD, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, New York, at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 671).

 

Pancreatic Cancer

Increase in Young-Onset Pancreatic Cancer May Be Due to Overdiagnosis of Early-Stage Endocrine Cancer

A recent analysis of pancreatic cancer data in young adults (aged 15–39) has found that although there is an increase in incidence, the mortality rate remains stable. According to Patel et al, who published their findings in the Annals of Internal Medicine, the rise in incidence is primarily due to an increase in the detection of smaller, early-stage endocrine cancer, and not an increase in pancreatic adenocarcinoma. The investigators explained that their findings reflect the detection of previously undetected disease, rather than a true increase in cancer occurrence.

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Breast Cancer

Award Recipients Announced for the 2024 San Antonio Breast Cancer Symposium

The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will honor two researchers for their significant contributions to breast cancer research during the 2024 SABCS. 2024 AACR Distinguished Lectureship in Breast Cancer Research ...

Advertisement

BRCA-Mutation Carriers With Prior Diagnosis of Early-Onset Breast Cancer May Benefit From Risk-Reducing Surgery

Matteo Lambertini, MD, PhD Patients with germline BRCA gene mutations and a history of early-onset breast cancer who underwent a bilateral risk-reducing mastectomy and/or a risk-reducing salpingo-oophorectomy had lower rates of recurrence, secondary breast and/or ovarian malignancies, and...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Immunotherapy
Lung Cancer

Metformin May Impact Immunotherapy in NSCLC

Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity, according to a recently published article in the Journal of the National Cancer Institute.1 The investigators looked at data from two groups of...

Multiple Myeloma

Will CAR T-Cell Therapy Be the Magic Bullet for My Multiple Myeloma?

Darlene Pruess Intense pain on the right side of my lower rib cage, in 2020, sent me first to my chiropractor for relief and then to my primary care provider for tests. Because of the location of the pain, the chiropractor thought I might be having a gallbladder attack, but the results from a ...

Fiber-Rich Diet May Help Prevent Complications After Stem Cell Transplant

Consuming a high-fiber diet after undergoing stem cell transplantation may help to reduce the risk of graft-vs-host disease (GVHD) by cultivating a healthy gut microbiome, according to research presented by Paredes et al at the 2024 American Society of Hematology (ASH) Annual Meeting &...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Issues in Oncology

The Lindy Effect and Open Cancer Surgery

The Lindy effect (also known as Lindy’s Law) is a theorized phenomenon by which the future life expectancy of some nonperishable thing, such as a technology or an idea, is proportional to its current age. Thus, the Lindy effect proposes the longer a period something has survived to exist or be used ...

Advertisement

Pirtobrutinib May Improve Survival Outcomes in Pretreated Patients With CLL or SLL

Researchers have found that the noncovalent Bruton's tyrosine kinase inhibitor (BTK) pirtobrutinib may offer superior progression-free survival in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to recent findings presented by Sharman et al at the 2024...

ASCO Post X Feed
Social Media Hub by Everwall